Compare Gilead Sciences, Inc. (GILD) vs HSBC Holdings plc (HSBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs HSBC Holdings plc — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while HSBC Holdings plc trades at $92.7 (market cap $319.39B). The key difference: HSBC Holdings plc is the larger of the two by market cap, and HSBC Holdings plc pays the higher dividend (4%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and HSBC Holdings plc for 36 Days on average.
| GILD | HSBC | |
|---|---|---|
Market Cap | $182.09B | $319.39B |
Volume | 4,960,247 | 2,543,839 |
Sector | Health | Financials |
52-Week High | $155.80 | $107.86 |
52-Week Low | $116.74 | $65.67 |
Typical Hold Time | 111 Days | 36 Days |
Enterprise Value | $205.15B | $216.95B |
Dividend Yield | 2.23% | 4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
HSBC trades at $93.71, down 3.97% today, with bearish technical signals dominating. The stock shows solid fundamentals with a P/E of 13.39 and net income margin of 34.54%, while recent earnings show mixed results with two beats and one miss. Recent corporate developments include expansion in technology banking and wealth management services, alongside strategic exits from lower-growth markets like Germany.
The outlook remains cautiously optimistic given strong profitability metrics and strategic growth initiatives, though near-term technical weakness and CFO transition risks warrant monitoring. Analyst consensus leans neutral with 52.38% hold ratings, reflecting balanced views on HSBC's Asia-focused growth strategy versus execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →
